SYNCOM FORMULATIONS (INDIA)
|
The Current P/E Ratio of SYNCOM FORMULATIONS (INDIA) is 63.98.
Share Price | ₹22.6 | Dec 11,2024 |
Market Cap | ₹2,120.6 Cr | |
Earnings-TTM | ₹33.1 Cr | TTM-Consolidated Results |
Price/Earnings | 63.98x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of SYNCOM FORMULATIONS (INDIA)
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,120.6 Cr] as on Dec 11,2024
(/) Earnings [ ₹33.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 63.98x ]
Thus, for SYNCOM FORMULATIONS (INDIA) , the investors are currently willing to pay 63.98 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of SYNCOM FORMULATIONS (INDIA) !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of SYNCOM FORMULATIONS (INDIA) over the last five years.
Historical PE (Price/Earnings) ratio chart of SYNCOM FORMULATIONS (INDIA)
PE Ratio Performance Analysis for SYNCOM FORMULATIONS (INDIA)
- SYNCOM FORMULATIONS (INDIA) 's p/e ratio for fiscal years ending Mar2024 to Mar2016 averaged 29.37x.
- SYNCOM FORMULATIONS (INDIA) 's operated at median p/e ratio of 27.63x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, SYNCOM FORMULATIONS (INDIA) 's p/e ratio peaked in Mar2022 at 46.32x.
- SYNCOM FORMULATIONS (INDIA) 's p/e ratio hit its five-year low in Mar2017 of 14.6x.
How does SYNCOM FORMULATIONS (INDIA) 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
SYNCOM FORMULATIONS (INDIA) | 33.15 | 63.98 | 2,120.6 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 39.10 | 435,407.0 |
CIPLA LTD | 4,485.22 | 26.18 | 117,443.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 19.11 | 103,338.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 23.09 | 99,244.9 |
DIVIS LABORATORIES LTD | 1,836.00 | 85.78 | 157,489.0 |
MANKIND PHARMA LTD | 2,124.86 | 49.46 | 105,098.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 63.38 | 114,202.0 |
LUPIN LTD | 2,651.94 | 36.97 | 98,055.1 |
AUROBINDO PHARMA LTD | 3,598.83 | 19.78 | 71,188.9 |
ABBOTT INDIA LTD | 1,284.66 | 47.75 | 61,336.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs SYNCOM FORMULATIONS (INDIA) 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 19.11x |
Max industry PE | 85.78x |
Median industry PE | 39.10x |
Average industry PE | 43.14x |
You may also like the below Video Courses